Int J Gynecol Cancer
July 2022
Background: Since the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, BRCA testing has evolved as a standard management in epithelial ovarian cancer.
Objective: To analyze the implementation of molecular testing and PARP inhibitor therapy in Germany.
Methods: The questionnaire contained 40 questions covering real-life data on genetic testing and the use of PARP inhibitors.